Sponsor or institution

Clinical trials and research at Immunomic Therapeutics, Inc.

• 2Clinical trials
• 2Countries

All recruiting trials (2)

• ITI-9001 for Japanese Cedar Pollen Allergy (first-in-human, single-arm, dose-escalation)

  This early study tests ITI-9001 in adults with Japanese cedar pollen allergy to see if it is safe, well tolerated, and capable of triggering helpful immune responses.

  Recruiting Phase 1 Immunomic Therapeutics, Inc. · Tokyo, Shinjuku-ku · NCT07726147

• Self-amplifying RNA vaccine ITI-5000 for stage 2-3 TNBC (two-part study)

  This Phase 1 trial tests ITI-5000, a saRNA cancer vaccine, in adults with stage 2-3 triple-negative breast cancer who finished standard treatment, to see if it’s safe and can provoke an immune response, alone or with approved immunotherapy.

  Recruiting at 4 sites Phase 1 Immunomic Therapeutics, Inc. · Los Angeles, California and 3 other locations · NCT07652242

Quick answers

How many clinical trials run by Immunomic Therapeutics, Inc. are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in Japan (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →